Condition
Proteinuric Kidney Disease
Total Trials
5
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (3)
P 4 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Terminated1
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06794996Phase 2Active Not RecruitingPrimary
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT06830629Phase 2RecruitingPrimary
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT05312879Phase 2RecruitingPrimary
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT07224776Phase 1Not Yet Recruiting
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
NCT01129557Phase 4TerminatedPrimary
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Showing all 5 trials